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Abstract
Aim: Gastric cancer is the cancer with the highest rate of peritoneal metastization and this type of spread is associated 
with a higher death rate compared to distant organ metastasis. The systemic chemotherapy has a minimal effect in 
peritoneal metastasis so new types of treatment have emerged. The authors revised the main studies done in pressurized 
intraperitoneal aerosol chemotherapy (PIPAC) and presented the main conclusions. 
Methods: A PubMed search was conducted focusing on PIPAC in gastric cancer. The MeSH database was searched with 
the terms: “Gastric cancer [MeSH] and intraperitoneal aerosol chemotherapy”. 
Results: Seven studies were analyzed. All the studies performed the technique with aerosol of doxorubicin and cisplatin. 
All cases were well tolerated, with minor adverse effects. Patients presented resolution of their abdominal symptoms and 
regression of macroscopic carcinomatosis. Cytoreductive surgery or hypertermic intraperitoneal chemotherapy could be 
performed in some patients with good response to PIPAC. The peritonitis caused by the chemotherapy was well tolerated. 
Conclusion: PIPAC can induce remission in end-stage and resistant disease with acceptable side effects, good safety levels 
for patients and health professionals, and quality of life improvement. 
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INTRODUCTION
Gastric cancer accounts for 6.8% of all cancers and it is the fifth most common cancer worldwide. Moreover, 
it is the third leading cause of death associated with cancer[1]. Gastric cancer has three ways to spread through 
the body: neoplasic cells could use the lymphatic system to spread to the lymph nodes, the blood stream 
to spread to distant organs, and the dissemination to peritoneal cavity. This last type of spread is called 
peritoneal metastatization. Gastric cancer is the cancer with the highest rate of peritoneal metastization and 
this type of spread is associated with a higher death rate compared to distant organ metastasis[2]. Without 
treatment, the median survival of these patients is 3-5 months.
Gastrectomy combined with D2 lymph node dissection remains the standard of care to manage gastric cancer 
in advanced stages, however, peritoneal metastases still needs to be optimized. The systemic chemotherapy 
has a minimal effect in peritoneal metastasis because the barrier between blood and peritoneum do not 
allow a high concentration of drug in the peritoneum[3]. An alternative to systemic chemotherapy consists 
in surgical removal of affected tissue combined with perioperative chemotherapy that includes: extensive 
intraoperative peritoneal lavage, neoadjucant intraperitoneal/systemic chemotherapy, hypertermic 
intraperitoneal chemotherapy (HIPEC), laparoscopic HIPEC and early postoperative intraperitoneal 
chemotherapy. The problems with these techniques are the need of complete cytoreduction in surgery and 
they are appropriate only for selected patients[4]. Moreover, this treatment is hindered by significant risks and 
side effects with a 30-day mortality rate of 5% in referral centers[5].
Recently, a new alternative therapy has emerged: pressurized intraperitoneal aerosol chemotherapy (PIPAC). 
This method can only be applied by laparoscopy and it is performed under general anesthesia. In this 
case, the chemotherapy is dispersed as pressurized aerosol into the peritoneal cavity by minimal invasive 
techniques, and left acting during 30 min. After this time, the gas is aspired. The recommendation is 3 
applications within 3 months. The most frequent adverse effects are fever, abdominal pain and nausea. 
Complications like infections, herniation or adhesion are uncommon due to minimally-invasive procedure 
[Figure 1].
METHODS
A PubMed search was conducted focusing on PIPAC in gastric cancer. The MeSH database was searched 
with the terms: “Gastric cancer [MeSH] and intraperitoneal aerosol chemotherapy”.
A total of 5 articles were collected. One study was excluded because it is written in Chinese. Then, 3 articles 
were added because they were recent and pertinent. Ultimately, 7 studies were included in the analysis.
RESULTS
The main results of the studies are listed in Table 1[6-12].
Nadiradze et al.[6] demonstrated that PIPAC is well tolerated but has no effect in patients with synchronous 
malignant pleural effusion. Twenty-four patients were included in the study, and 60 PIPAC were performed: 
71% of the patients had repeated the procedure; no procedure-related mortality was reported; the mean 
survival time was 15.4 months; and objective tumor response was observed in 50% of the patients. 
Hübner et al.[7] had used as exclusion criteria for PIPAC the thrombosis of portal vein, intestinal occlusion 
and some clinical condition that could be a contra-indication for capnoperitoneum. Fifty-eight patients 
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were included and 127 PIPAC procedures were performed. One PIPAP was excluded due to incidental small 
bowel injury. 
Tempfer[8] reported some studies, only one with gastric cancer patients. The main emphasis was ovarian 
cancer. The reported gastric cancer patient was the same patient described in Solass et al.[9] study. 
Solass et al.[9] followed 3 patients, 1 with gastric cancer, 1 with ovarian cancer and 1 with appendix cancer. In 
the gastric cancer patient, an early hospital discharge was possible and no severe side effects were observed. 
Globally, 2 patients showed a complete histological remission and 1 showed a partial remission. It was 
observed a mean survival of 288 days. 
Teixeira Farinha et al.[10] followed 42 patients that underwent PIPAC and evaluated their quality of life during 
the treatment time and main symptoms.  
  
Girshally et al.[11] performed PIPAC in patients with colorectal cancer, appendiceal cancer, ovarian cancer, 
peritoneal mesothelioma and pseudomyxoma peritoneal as a neoadjuvant treatment in peritoneal metastasis 
not eligible for cytoreductive surgery and HIPEC. The gastric cancer patients have no extensive peritoneal 
disease so they were not included. 
Alyami et al.[12] evaluated the postoperative outcome of 164 procedures of PIPAC using the peritoneal cancer 
index. 
DISCUSSION
Intraperitoneal chemotherapy is associated to local toxicity due to high drug concentration in peritoneal 
cavity and the repeated delivery, which leads to chemical peritonitis and a systemic inflammatory response.
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Figure 1. Pressurized intraperitoneal aerosol chemotherapy (PIPAC). Two trocars are inserted into the peritoneal cavity; then CO2 is insufflated 
in a pressure of 12 mmHg. Small tissue samples of the tumor are retrieved (biopsy). Then, the chemotherapy is dispersed as pressurized 
aerosol inside the peritoneal cavity. At the end of the procedure (30 min), the gas is released over a closed aerosol waste system (CAWS)
No significant renal toxicity was documented in these studies, however a low-grade liver toxicity was 
reported in a quarter of patients in Nadiradze et al.[6] study. 
Hübner et al.[7] concluded that no learning curve was observed because the operation time did not decrease 
over time. Some minor complications were observed during this study such as constipation, ileus, transitory 
neutropenia, urinary retention and wound complications. Looking to these effects, the procedure seems to 
be safe. Only one patient died due to cardiac arrhythmia. 
Tempfer et al.[8] reported that delivering chemotherapy as an aerosol did not represent a risk to health 
care workers so, it could be used safely in the clinical setting. Moreover, the quality of life improved over 
5-6 months. 
Solass et al.[9] achieved 2 complete remissions and all 3 cases had tumor response. The mean survival of the 3 
patients was 288 days, and the gastric cancer patients died 109 days after the procedure. 
Teixeira Farinha et al.[10] concluded that PIPAC had no undesirable impact on quality of life of patients with 
peritoneal carcinomatosis. A shorter hospital stay was associated with patients with better scores at baseline 
in quality of life. Nondigestive and digestive symptoms remained uncharged after repeated treatments. 
Girshally et al.[11] concluded that patients with extensive peritoneal disease that were treated with PIPAC as 
neoadjuvant therapy had worse prognosis than those treated primarily with citoreductive surgery and HIPEC 
in limited disease. However, when the cytoreductive surgery and HIPEC were not possible due to extensive 
disease, PIPAC was successful in diminishing the tumor burden and allowed forward procedures. 
Alyami et al.[12] found that symptoms related to peritoneal carcinomatosis like ascites, pain or transit 
disorders were decreased during PIPAC. Some major complications occurred in 9.7% of the patients and 5 
died within 30 days of the PIPAC procedure. 
Table 1. Main conclusions of the studies
Authors Year Patients Aerosol Conclusion
Nadiradze et al .[6] 2016 24 patients with peritoneal metastases 
from gastric cancer resistant to systemic 
chemotherapy and with no option for 
cytoreductive surgery and HIPEC
Doxorubicin 1.5 mg/m2 
followed by cisplatin 
7.5 mg/m2
Follow-up: 248 days;
median survival time: 15.4 months;
survival after follow-up time: 13 patients;
objective tumor response in 12 patients;
complete histological regression in 6 
patients
Hübner et al .[7] 2017 58 patients with peritoneal disease from 
digestive cancer that was persistent or 
progressive after prior standard surgical 
and/or medical treatment
Doxorubicin 1.5 mg/m2 in 
combination with cisplatin 
7.5 mg/m2
Intraoperative event rate: 11%;
deaths after the procedure: 1 patient
Tempfer[8] 2015 1 patient with peritoneal disease from 
gastric cancer after gastrectomy and 2 
chemotherapy lines
Doxorubicin 1.5 mg/m2 
with cisplatin 7.5 mg/m2
Survival of 109 days;
the patient developed liver and bone 
metastases but with no evidence of 
peritoneal metastases
Solass et al .[9] 2014
Teixeira Farinha et al .[10] 2017 42 patients: 21 patients with 
chemoresistent isolated peritoneal 
carcinomatosis from gynecological 
origin, 14 patients from colorectal origin 
and 3 from gastric origin
Not mentioned PIPAC had no negative impact on patients’ 
overall quality of life or in main symptoms;
there was no worse quality of life in PIPAC 
patients with high intraperitoneal tumor 
load
Girshally et al .[11] 2016 9 patients with advanced peritoneal 
disease no candidates for primary 
cytoreductive surgery and HIPEC
Doxorubicin 1.5 mg/m2 
followed by cisplatin 
7.5 mg/m2
7 patients obtained objective radiological 
tumor regression;
8 patients obtained objective major 
histological regression
Alyami et al .[12] 2017 73 patients with non-resectable 
peritoneal carcinomatosis (26 from 
gastric cancer)
Cisplatin 7.5 mg/m2 
followed by doxorubicin 
1.5 mg/m2
63.5% of patients presented complete 
regression of symptoms;
peritoneal cancer index improved in 64.5% 
of patients
PIPAC: pressurized intraperitoneal aerosol chemotherapy; HIPEC: hypertermic intraperitoneal chemotherapy
Page 4 of 6                              Macedo et al. J Cancer Metastasis Treat 2018;4:8  I  http://dx.doi.org/10.20517/2394-4722.2017.72
Searching in the ClinicalTrials.gov registry, we found 1 clinical trial completed in Germany (PIPAC-GA01), 
but 4 more trials recruiting: 1 in Italy, 1 in Singapore, 1 in Germany and the last 1 in 14 countries. PIPAC-
GA01 is a clinical trial with 35 patients where cisplatin and doxorubicin will be applied in 3 single doses in 
6 weeks intervals. The safety and efficacy in terms of the clinical benefit rate will be accessed, but no results 
were published yet.
At this stage, it is not possible to define indications and contraindications for PIPAC. The authors think that 
this method could be a good option for patients who have done systemic chemotherapy with severe side 
effects, patients with renal failure, hepatic failure or patients with cardiac toxicity. On the other hand, it is no 
option for patients with end-stage disease or malignant pleural effusion.
PIPAC was tested mainly in ovarian cancer, gastric cancer and colon cancer, and it seems feasible in most 
patients with refractory carcinomatosis of various origins. There were no consistent studies comparing what 
type of cancer will benefit the most with this technique. 
This procedure could be a new palliative treatment option because it may increase quality of life. The next 
step should be the appliance of this technique in patients in an early stage of peritoneal carcinomatosis to 
access the efficacy. 
DECLARATIONS
Authors’ contributions
Concept and design of the review, article analysis and interpretation: all authors
Drafting the manuscript: Macedo F, Ladeira K
Manuscript revising: Longatto-Filho A, Martins SF
Approved the final version to be published: all authors
Data source and availability
All the information analysed during the current study are available in the Pubmed Repository (https://www.
ncbi.nlm.nih.gov/pubmed/).
Financial support and sponsorship
None. 
Conflicts of interest
There are no conflicts of interest. 
Patient consent
Not applicable.
Ethics approval
Not applicable.
Copyright
© The Author(s) 2018. 
REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality 
worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
2. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A; ESMO Guidelines Working Group. Gastric cancer: ESMO clinical 
Macedo et al. J Cancer Metastasis Treat 2018;4:8  I  http://dx.doi.org/10.20517/2394-4722.2017.72                              Page 5 of 6
practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v50-4. 
3. Yonemura Y, Endou Y, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Miura M, Li Y. Surgical treatment for 
peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol 2010;36:1131-8.
4. Yonemura Y, Canbay E, Endou Y, Ishibashi H, Mizumoto A, Miura M, Li Y, Liu Y, Takeshita K, Ichinose M, Takao N, Hirano M, Sako S, 
Tsukiyama G. Peritoneal cancer treatment. Expert Opin Pharmacother 2014;15:623-36.
5. Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, Schiller D. Treatment of gastric cancer with peritoneal carcinomatosis 
by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol 2011;104:692-8.
6. Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy 
(PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg 2016;20:367-73.
7. Hübner M, Grass F, Teixeira-Farinha H, Pache B, Mathevet P, Demartines N. Pressurized intraperitoneal aerosol chemotherapy - 
practical aspects. Eur J Surg Oncol 2017;43:1102-9.
8. Tempfer C. Pressurized intraperitoneal aerosol chemotherapy as an innovative approach to treat peritoneal carcinomatosis. Med 
Hypotheses 2015;85:480-4
9. Solass W, Kerb R, Mürdter T, Giger-Pabst U, Strumberg D, Tempfer C, Zieren J, Schwab M, Reymond MA. Intraperitoneal 
chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. 
Ann Surg Oncol 2014;21:553-9. 
10. Teixeira Farinha H, Grass F, Kefleyesus A, Achtari C, Romain B, Montemurro M, Demartines N, Hübner M. Impact of pressurized 
intraperitoneal aerosol chemotherapy on quality of life and symptoms in patients with peritoneal carcinomatosis: a retrospective cohort 
study. Gastroenterol Res Pract 2017;2017:4596176. 
11. Girshally R, Demtröder C, Albayrak N, Zieren J, Tempfer C, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy 
(PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 
2016;14:253.
12. Alyami M, Gagniere J, Sgarbura O, Cabelguenne D, Villeneuve L, Pezet D, Quenet F, Glehen O, Bakrin N, Passot G. Multicentric 
initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable 
peritoneal carcinomatosis. Eur J Surg Oncol 2017;43:2178-83. 
Page 6 of 6                               Macedo et al. J Cancer Metastasis Treat 2018;4:8  I  http://dx.doi.org/10.20517/2394-4722.2017.72
